The new drug can be taken at any time of day without food or water restrictions
The U.S. Food and Drug Administration (FDA) has approved a new weight loss pill — orforglipron (brand name Foundayo) from Eli Lilly. It is the second oral GLP-1 class drug on the market, but the first that can be taken without any restrictions: at any time of day, with or without food, washed down with anything. Sales will begin as early as next Monday, and the price will start at $25 for some patients.
How Orforglipron Works — The New GLP-1 Weight Loss Drug
Orforglipron belongs to the class of GLP-1 receptor agonists — the same class as the famous injectable drugs Wegovy and Zepbound. They all mimic the action of the natural hormone GLP-1 (glucagon-like peptide-1), which is produced in the gut after eating. This hormone signals the brain that the body is full, slows stomach emptying, and reduces appetite.
But there is a fundamental difference. Orforglipron is a so-called small molecule. This means that the drug is chemically simpler and more stable than peptide GLP-1 analogs. That is precisely why the pill can be taken without restrictions: there is no need to wait 30 minutes before eating, no need to take it on an empty stomach, and no need to wash it down strictly with water. For comparison, the Wegovy pill from Novo Nordisk is a peptide drug that must be taken in the morning on an empty stomach with a small amount of water, followed by 30 minutes of not eating or drinking.
The pills can be taken regardless of food and water intake.
It might seem like a minor detail, but for people who take a pill every day for months and years, the absence of strict intake rules is a significant convenience. It reduces the likelihood of errors and missed doses.
How Many Kilograms Can You Lose With Orforglipron
The results of a clinical study published in the New England Journal of Medicine are as follows: more than 3,000 adults with obesity took orforglipron for over 16 months. Participants receiving the maximum dose (36 mg) lost an average of 11.2% of their body weight — approximately 11 kilograms. In the control group taking a placebo, the loss was 2.1% — less than 2.3 kg.
In addition to weight loss, study participants experienced a reduction in waist circumference, lower blood pressure, and improved triglyceride and cholesterol levels.
It should be honestly noted: these results are more modest than those of injectable analogs. Injectable Zepbound from the same Eli Lilly provides an average of 21% weight loss, while injectable Wegovy delivers about 15%. But a pill is a pill: many patients prefer it to injections, even if the effect is slightly lower.
Side Effects of Orforglipron and Who It Is Suitable For
The side effects of orforglipron are generally typical for the entire GLP-1 class: mainly gastrointestinal issues — nausea, diarrhea, and abdominal discomfort. Due to side effects, 5% to 10% of study participants discontinued the drug. In the placebo group, about 3% dropped out.
The drug is approved for the treatment of obesity and related conditions. It is a prescription medication, not an over-the-counter “diet pill” that can be bought at will. The decision to prescribe it is made by a doctor based on the patient’s diagnosis and clinical profile.
How Much Does Orforglipron Cost and Why It Is Cheaper Than Alternatives
Eli Lilly has announced several pricing options. For patients with medical insurance using the company’s discount card, the cost may start at $25 per month. For those paying out of pocket, the price will range from $149 to $349 per month depending on the dose.
This is important context: roughly one in eight adults in the U.S. has already tried injectable GLP-1 drugs, but many cannot afford the expensive injections. A pill with a lower price could make the therapy more accessible to a wider range of people.
Sales of the new drug in U.S. pharmacies will begin as early as next week
Why the FDA Quickly Approved Orforglipron
The speed of approval is worth noting separately. The FDA reviewed Eli Lilly’s application in 50 days — this was made possible by a new expedited drug review program. Normally, the process takes many months. Expedited approval does not mean the review was less thorough — it means the bureaucratic stages were optimized.
It can be said that the market for oral obesity treatment drugs is only beginning to take shape. Just a year ago, GLP-1 weight loss pills did not exist at all, and now there are already two — both from the world’s largest pharmaceutical companies. For patients, this means choice, competition, and, in the long run, lower prices. This is important, as obesity has already affected more than a billion people worldwide (and that is only the official statistics).
For now, however, these are prescription drugs approved only in the United States. When and whether they will appear on other markets remains an open question.
